Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Drug attack on Tough-to-Treat prostate cancer

NCT ID NCT07002320

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a new drug called SX-682 to an existing prostate cancer drug (apalutamide) is safe and can help control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It will involve about 78 men whose cancer has progressed despite prior therapy. The main goals are to find a safe dose and see if the combination can shrink tumors or slow their growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Belfast Health and Social Care Trust

    NOT_YET_RECRUITING

    Belfast, BT9 7AB, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Cambridge University Hospitals NHS Foundation Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oncology Institute of Southern Switzerland

    NOT_YET_RECRUITING

    Bellinzona, CH6500, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • The Royal Marsden NHS Foundation Trust - Drug Development Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)